Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis.

IF 0.5 Q4 OPHTHALMOLOGY Middle East African Journal of Ophthalmology Pub Date : 2021-09-25 eCollection Date: 2021-04-01 DOI:10.4103/meajo.meajo_134_21

Joanna S Saade, Rachid Istambouli, Marwan AbdulAal, Rafic Antonios, Rola N Hamam

{"title":"Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis.","authors":"Joanna S Saade, Rachid Istambouli, Marwan AbdulAal, Rafic Antonios, Rola N Hamam","doi":"10.4103/meajo.meajo_134_21","DOIUrl":null,"url":null,"abstract":"Purpose: The topical nonsteroidal anti-inflammatory drug bromfenac 0.09% has a potential benefit in uveitic macular edema (UME) with a safe side effect profile. The aim of the study is to assess the efficacy of bromfenac sodium solution in the treatment of UME.Methods: The charts of 10 patients with macular edema due to noninfectious uveitis treated with bromfenac 0.09% were reviewed retrospectively. The main outcomes studied were the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) compared 4 months before bromfenac initiation, at the time of its initiation, and 4 months later.Results: Twelve eyes of 10 patients were included. BCVA and CRT were unchanged 4 months befoew bromfenac compared to the time of bromfenac initiation (P = 1.0 and P = 0.2, respectively). There were a significant improvement in BCVA after 4 months of bromfenac treatment (P = 0.043) and a significant decrease in CRT (P = 0.002). Subretinal fluid resolved completely in 8/9 eyes, and 4/9 eyes had a complete resolution of cystoid macular edema at 4 months.Conclusion: Bromfenac may be a useful addition to the treatment of UME.","PeriodicalId":18740,"journal":{"name":"Middle East African Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2021-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547661/pdf/","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East African Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/meajo.meajo_134_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Purpose: The topical nonsteroidal anti-inflammatory drug bromfenac 0.09% has a potential benefit in uveitic macular edema (UME) with a safe side effect profile. The aim of the study is to assess the efficacy of bromfenac sodium solution in the treatment of UME.

Methods: The charts of 10 patients with macular edema due to noninfectious uveitis treated with bromfenac 0.09% were reviewed retrospectively. The main outcomes studied were the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) compared 4 months before bromfenac initiation, at the time of its initiation, and 4 months later.

Results: Twelve eyes of 10 patients were included. BCVA and CRT were unchanged 4 months befoew bromfenac compared to the time of bromfenac initiation (P = 1.0 and P = 0.2, respectively). There were a significant improvement in BCVA after 4 months of bromfenac treatment (P = 0.043) and a significant decrease in CRT (P = 0.002). Subretinal fluid resolved completely in 8/9 eyes, and 4/9 eyes had a complete resolution of cystoid macular edema at 4 months.

Conclusion: Bromfenac may be a useful addition to the treatment of UME.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

溴芬酸0.09%治疗继发于非感染性葡萄膜炎的黄斑水肿。

目的:局部非甾体抗炎药溴芬酸0.09%对葡萄膜性黄斑水肿(UME)有潜在的益处，且副作用安全。本研究的目的是评估溴芬酸钠溶液治疗UME的疗效。方法:回顾性分析0.09%溴芬酸治疗非感染性葡萄膜炎所致黄斑水肿10例的临床资料。研究的主要结果是比较溴芬酸起始治疗前4个月、起始治疗时和4个月后的最佳矫正视力(BCVA)和视网膜中央厚度(CRT)。结果:纳入10例患者12只眼。与溴芬酸起始治疗时间相比，溴芬酸治疗前4个月的BCVA和CRT没有变化(P = 1.0和P = 0.2)。溴芬酸治疗4个月后BCVA显著改善(P = 0.043)， CRT显著降低(P = 0.002)。8/9只眼的视网膜下积液完全消失，4/9只眼的黄斑囊样水肿在4个月时完全消失。结论:溴芬酸可能是治疗UME的有效补充。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Middle East African Journal of Ophthalmology OPHTHALMOLOGY-

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Middle East African Journal of Ophthalmology (MEAJO), published four times per year in print and online, is an official journal of the Middle East African Council of Ophthalmology (MEACO). It is an international, peer-reviewed journal whose mission includes publication of original research of interest to ophthalmologists in the Middle East and Africa, and to provide readers with high quality educational review articles from world-renown experts. MEAJO, previously known as Middle East Journal of Ophthalmology (MEJO) was founded by Dr Akef El Maghraby in 1993.